Volume 62, Issue 1, Pages (July 2012)

Slides:

Advertisements

Similar presentations

Volume 64, Issue 5, Pages (November 2013)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 71, Issue 6, Pages (June 2017)

MRI as an Alternative to CT-Guided Biopsy of Adrenal Masses in Patients With Lung Cancer Lawrence H Schwartz, Michelle S Ginsberg, Michael E Burt, Karen.

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Volume 64, Issue 6, Pages (December 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 27, Issue 4, Pages (December 2016)

Bone scan showing bone metastases

A Solitary Bone Lesion in a Patient With Previous Breast Cancer and the Importance of Bone Biopsy: A Case Report and a Review of Guidelines Gaia Schiavon,

Whole-body diffusion-weighted magnetic resonance imaging: Current evidence in oncology and potential role in colorectal cancer staging Doenja M.J. Lambregts,

Volume 70, Issue 5, Pages (November 2016)

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 62, Issue 5, Pages (November 2012)

Potential and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in Kidney, Prostate, and Bladder Cancer Including Pelvic Lymph Node Staging:

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 61, Issue 5, Pages (May 2012)

Volume 73, Issue 5, Pages (May 2018)

Volume 54, Issue 4, Pages (October 2008)

Volume 67, Issue 3, Pages (March 2015)

Volume 51, Issue 4, Pages (April 2007)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Volume 62, Issue 2, Pages (August 2012)

Volume 71, Issue 1, Pages (January 2017)

Volume 70, Issue 5, Pages (November 2016)

Volume 64, Issue 6, Pages (December 2013)

Volume 55, Issue 4, Pages (April 2009)

Volume 53, Issue 5, Pages (May 2008)

Volume 71, Issue 5, Pages (May 2017)

Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer Arnauld Villers, Philippe Puech, Xavier Leroy, Jacques Biserte,

Volume 52, Issue 3, Pages (September 2007)

Volume 64, Issue 6, Pages (December 2013)

Volume 72, Issue 3, Pages (September 2017)

Volume 66, Issue 1, Pages (July 2014)

Volume 64, Issue 5, Pages (November 2013)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 71, Issue 1, Pages 1-3 (January 2017)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 62, Issue 1, Pages (July 2012)

Volume 67, Issue 6, Pages (June 2015)

Volume 57, Issue 2, Pages (February 2010)

Volume 67, Issue 4, Pages (April 2015)

Laurent Boccon-Gibod European Urology Supplements

Volume 64, Issue 6, Pages (December 2013)

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,

Volume 58, Issue 1, Pages 1-7 (July 2010)

European Urology Oncology

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 53, Issue 3, Pages (March 2008)

Volume 65, Issue 4, Pages (April 2014)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Antonio Alcaraz, Pierre Teillac European Urology Supplements

Volume 66, Issue 6, Pages (December 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Long-Term Hormonal Therapy: Who Would Benefit?

Intramedullary Reactive Fibrosis as Mimic of Prostate Cancer Bone Metastasis on 11C- Choline Positron Emission and Computed Tomography Tyler Trump, BS,

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

MRI as an Alternative to CT-Guided Biopsy of Adrenal Masses in Patients With Lung Cancer Lawrence H Schwartz, Michelle S Ginsberg, Michael E Burt, Karen.

Volume 69, Issue 1, Pages (January 2016)

Bob Djavan European Urology Supplements

Volume 52, Issue 2, Pages (August 2007)

Volume 53, Issue 6, Pages (June 2008)

Volume 4, Issue 1, Pages (February 2006)

A 53-year-old patient with fibrosing mediastinitis

Presentation transcript:

Volume 62, Issue 1, Pages 68-75 (July 2012) Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer? Frédéric E. Lecouvet, Jawad El Mouedden, Laurence Collette, Emmanuel Coche, Etienne Danse, François Jamar, Jean-Pascal Machiels, Bruno Vande Berg, Patrick Omoumi, Bertrand Tombal European Urology Volume 62, Issue 1, Pages 68-75 (July 2012) DOI: 10.1016/j.eururo.2012.02.020 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Whole-body magnetic resonance imaging (MRI) versus bone scintigraphy (BS) for bone metastasis detection in a 70-yr-old patient with newly diagnosed prostate cancer (prostate-specific antigen 142 ng/ml; Gleason score 9). (A) BS shows two foci of increased uptake (arrows). (B) Coronal T1 and (C) diffusion-weighted MRI images of the whole body confirm bone metastases within the right glenoid and left iliac bone (arrows). (D) The best valuable comparator confirms metastasis, with significant progression of bone involvement at 6 mo. European Urology 2012 62, 68-75DOI: (10.1016/j.eururo.2012.02.020) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Whole-body magnetic resonance imaging (MRI) versus false-negative bone scintigraphy (BS) for bone metastasis detection in a 65-yr-old patient with newly diagnosed prostate cancer (prostate-specific antigen 18 ng/ml; Gleason score 7 [4 + 3]). (A) BS (anterior-posterior and posterior-anterior views) shows no significant lesion. (B) Coronal T1 and (C) diffusion-weighted MRI images of the whole body confirm bone metastases within L3 and the left iliac bone (arrows). European Urology 2012 62, 68-75DOI: (10.1016/j.eururo.2012.02.020) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Whole-body magnetic resonance imaging (MRI) versus computed tomography (CT) for lymph node metastasis detection in a 68-yr-old patient with rising prostate-specific antigen (PSA) while undergoing androgen-deprivation therapy (PSA doubling time: 6.4 mo). (A) Coronal T1 and (B) diffusion-weighted MRI of the whole body show multiple abnormal lymph nodes within the iliac and lombo-aortic regions (arrows). (C) These enlarged lymph nodes are confirmed on the corresponding coronal reformatted abdomino-pelvic CT image (arrows). (D, E) Close-up views of the node measurements on MRI and CT images. European Urology 2012 62, 68-75DOI: (10.1016/j.eururo.2012.02.020) Copyright © 2012 European Association of Urology Terms and Conditions